CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Actiponin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01667224
NCT01667224Phase 2Completed
CompareCT.gov

Actiponin Supplementation Reduces Abdominal Fat Area, Weight, Body Fat Mass and BMI in Obese Korean Subjects.

Chonbuk National University Hospital·interventional·Posted Aug 17, 2012·Updated Feb 23, 2017

In Brief

A Phase 2 clinical trial evaluating Actiponin and Placebo for Obesity. Completed, enrolled 80 participants.

Detailed Summary

Obesity is a major health issue worldwide; there is a constant raise in obesity related death each year. In vitro and animal studies elucidated Actiponin as a novel anti-obesity agent. However, the efficacy and safety of Actiponin supplementation on body weight regulation in humans are lacking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2012
Enrollment StartOct 1, 2009
Primary CompletionAug 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.9 years ago

Interventions

Actiponindietary

The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.

Placebodietary

Amount and calorie of placebo are same with Actiponin.